Compare ImmunityBio Inc. Common Stock (IBRX) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Norwegian Cruise Line Holdings Ltd — how do they compare? ImmunityBio Inc. Common Stock trades at $10.01 (market cap $10.33B), while Norwegian Cruise Line Holdings Ltd trades at $15.51 (market cap $6.91B). The key difference: ImmunityBio Inc. Common Stock is the larger of the two by market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| IBRX | NCLH | |
|---|---|---|
Market Cap | $10.33B | $6.91B |
Volume | 11,745,198 | 25,654,210 |
Sector | Health | Consumer Cyclical |
52-Week High | $11.55 | $25.02 |
52-Week Low | $1.98 | $14.12 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $10.79B | $21.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Norwegian Cruise Line Holdings (NCLH) trades at $15.49, down 0.13% on the day, with a neutral technical signal and bearish moving averages. The company reported strong recent earnings beats and expects Q3 2026 results to exceed guidance, with revenue growth from $9.8B in 2025 to $10.2B projected for 2026. Valuation metrics appear attractive with a P/E of 9.12 and P/S of 0.72, while analyst consensus remains bullish with a $20.86 price target.
NCLH presents a compelling value opportunity with solid fundamentals and positive earnings momentum, though investors face risks from high debt levels, yield pressure, and competitive industry dynamics. The stock's current discount to analyst targets suggests potential upside if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
